Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study-MedSci.cn

Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study

Engert, A; Domenech, ED; Rueda, A; Armand, P; Trneny, M; Feldman, T; Ansell, S; Provencio, M; Jaeger, U; Cohen, JB; Savage, KJ; Willenbacher, W; Sacchi, M; Sumbul, A; Ramchandren, R

ONCOLOGY RESEARCH AND TREATMENT, 2018; 41 (): 273

科室
- - 订阅+
  - 更多科室
工具
服务